Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9838541 | 1.00 | MAPK1 (0.31) | MAPK1 | |
| Hydrochloric Acid SCHEMBL28575505 | 0.98 | MAPK1 (0.30) | MAPK1 | |
| Hydrochloric Acid SCHEMBL7624938 | 0.98 | MAPK1 (0.30) | MAPK1 | |
| SCHEMBL7442843 | 0.95 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL22388041 | 0.91 | — | — | |
| SCHEMBL13676325 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL28566347 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL28564693 | 0.71 | — | — | |
| SCHEMBL5731681 | 0.70 | — | — | |
| SCHEMBL7305562 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110804051-A | Preparation method of granisetron intermediate | 杭州励德生物科技有限公司 | 2020-02-18 | — | — | CN | claimed |
| CN-102234231-B | 1-substituted-2-substituted-4- aryl substituted-butyl-2-alkene 1, 4-diketone compound, its preparation method and application | SHANGHAI INST MATERIA MEDICA | 2015-01-07 | — | — | CN | claimed |
| CN-102234231-A | 1-substituted-2-substituted-4- aryl substituted-butyl-2-alkene 1, 4-diketone compound, its preparation method and application | SHANGHAI INST MATERIA MEDICA | 2011-11-09 | — | — | CN | claimed |
| CN-1190436-C | Process for preparing granisetron and its salt | HAIZHENG PHARMACEUTICAL CO LTD (CN) | 2005-02-23 | — | — | CN | claimed |
| CN-1451660-A | Process for preparing granisetron and its salt | HAIZHENG PHARMACEUTICAL CO LTD (CN) | 2003-10-29 | — | — | CN | claimed |
| WO-2025064788-A2 | CCR5 CONJUGATES AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-119161244-A | Method for preparing single-configuration tropine acid amine salt and method for resolving tropine acid | 成都倍特药业股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| CN-118265711-A | Chromanamidine monocyclic lactam antibiotics | 默沙东有限责任公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2023219548-A1 | SELECTIVE DOPAMINE INCREASE | SOBRERA PHARMA AB (SE) | 2023-11-16 | — | — | WO | disclosed |
| WO-2022241188-A1 | ENANTIOSELECTIVE SYNTHESIS OF AMINOTROPANE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-11-17 | — | — | WO | disclosed |
| US-20220363693-A1 | HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-11-17 | — | — | US | disclosed |
| CN-1050875-A | AROYL-URRES | WYETH JOHN & BROTHER LTD (GB) | 1991-04-24 | — | — | CN | disclosed |
| EP-0422846-A2 | Aroyl-ureas | JOHN WYETH & BROTHER LIMITED (GB) | 1991-04-17 | — | — | EP | disclosed |
| US-4983600-A | Antiemetics, antianxiety agents, gastrointestinal disorders | JOHN WYETH & BROTHER LIMITED (GB) | 1991-01-08 | — | — | US | disclosed |
| US-4959367-A | ANALGESICS, TRANQUILIZERS, GASTROINTESTINAL, CNS | BEECHAM GROUP P.L.C. (GB) | 1990-09-25 | — | — | US | disclosed |
| EP-0361629-A2 | Heterocyclic compounds | JOHN WYETH & BROTHER LIMITED (GB) | 1990-04-04 | — | — | EP | disclosed |
| EP-0323077-A1 | Heterocyclic compounds | JOHN WYETH & BROTHER LIMITED (GB) | 1989-07-05 | — | — | EP | disclosed |
| EP-0315390-A2 | Novel 4-oxobenzotriazines and 4-oxoquinazolines | BEECHAM GROUP PLC (GB) | 1989-05-10 | — | — | EP | disclosed |
| US-4432983-A | GASTRIC ACID INHIBITORS | RESEARCH CORPORATION (US) | 1984-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363693-A1 | HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN9, PTPN7 | MAPK1 295/4885 |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | PTPN1, PTPN9, PTPN7 | MAPK1 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.